POTENTIA PHARMACEUTICALS, INC

Company Information
Address POTENTIA PHARMACEUTICALS, INC
201 E JEFFERSON ST, STE 312
LOUISVILLE, KY, 40202


Information

DUNS: 144375263

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Targeting drug delivery nanoparticles to sites of inflammation

    Amount: $977,329.00

    DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration ...

    STTRPhase II2008Department of Health and Human Services
  2. Targeting drug-delivery nanoparticles to sites of inflammation

    Amount: $342,741.00

    DESCRIPTION (provided by applicant): The purpose of this project is to develop a nanoparticle-based drug delivery system for use in the treatment of the exudative form of aged-related macular degenera ...

    STTRPhase I2006Department of Health and Human Services
  3. Preventing choroidal neovascularization by long-term transscleral drug delivery

    Amount: $293,017.00

    DESCRIPTION (provided by applicant): Age-related Macular Degeneration (ARMD) is the leading cause of blindness for individuals over fifty-five years of age that live in the industrialized world. With ...

    STTRPhase I2006Department of Health and Human Services
  4. Bypassing fluidics in proteomic screening

    Amount: $504,000.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new, groundbreaking technology for the rapid identification of ligands for proteins. Every year, the pharmaceuticals indu ...

    SBIRPhase I2004Department of Health and Human Services
  5. Modified bacterial system for vivo direction evolution

    Amount: $252,798.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new genetic system that will mimic the natural process of evolution for a selected subset of genes inside of a bacterial ...

    SBIRPhase I2004Department of Health and Human Services
  6. Targeting drug-delivery nanoparticles to sites of inflammation

    Amount: $342,741.00

    DESCRIPTION (provided by applicant): The purpose of this project is to develop a nanoparticle-based drug delivery system for use in the treatment of the exudative form of aged-related macular degenera ...

    SBIRPhase IDepartment of Health and Human Services
  7. Preventing choroidal neovascularization by long-term transscleral drug delivery

    Amount: $293,017.00

    DESCRIPTION (provided by applicant): Age-related Macular Degeneration (ARMD) is the leading cause of blindness for individuals over fifty-five years of age that live in the industrialized world. With ...

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government